ClinicalTrials.gg
CompletedNCT04027517Updated Mar 22, 2021

A Study to Evaluate Efficacy and Safety of JTZ-951 Compared to Darbepoetin Alfa in Korean Renal Anemia Patients Receiving Hemodialysis.

A Phase 3 interventional study of JTZ-951 and Darbepoetin Alfa in Anemia of Chronic Kidney Disease, sponsored by JW Pharmaceutical. Completed at 1 site in Korea, Republic of. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2021-03-22.

Sponsored by JW Pharmaceutical · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Registered 5 months after the study started (first participant enrolled Jan 2019, registered Jul 2019).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
172
Allocation
Randomized
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 57 studies in Anemia with a site in Korea, Republic of — 8 open to participants now, 14 under way, 10 of them phase 3. Anemia · Korea, Republic of.

Enrollment
35th of 54
172 · median 228
Started
2019
with 2 others
Phase 3
32 of 57
5 open now
Registered
39th of 57
by date

Among the 57 studies in Anemia with a site in Korea, Republic of, this one is the 35th largest by enrollment of the 54 interventional ones that give a count, is one of 3 that started in 2019, is one of 32 in phase 3, and was the 39th registered.

Anemia

1,810 studies on the registry are indexed under Anemia; 215 are open to participants now.

Browse Anemia studies →

Open to participants now

8 of the 57 studies in Anemia with a site in Korea, Republic of are open now. Recruiting first, the newest first:

3 more — sign in →

All 8 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 122 Anemia studies recruiting now, 67 (55%) set no upper age limit and 37 (30%) stop at 75 or younger; 34 take children under 18; 23 take healthy volunteers.

This study: 19 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 57 studies in Anemia with a site in Korea, Republic of, or all of them as a file.
02

Study summary

JTZ-951 is a currently being developed as a treatment for renal anemia. This study aims to evaluate the efficacy and safety of JTZ-951 following a switch from erythropoiesis-stimulating agent (ESA) in Korean subjects receiving HemoDialysis with renal anemia.

This study is a Phase III, open, active-controlled, parallel-group, multi-center study.

The total duration of the study will be 30 weeks including screening, treatment and follow-up.

Read the detailed description

The primary objective is to demonstrate non-inferiority of JTZ-951 to darbepoetin alfa.

03

Conditions studied

  • Anemia of Chronic Kidney Disease

Browse trials for

04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Korean patients aged ≥ 19 years at the time of consent
  2. Patients receiving hemodialysis (including hemodiafiltration) consistently three times a week for at least 12 weeks before Scr Visit 1
  3. Patients with TSAT (Transferrin saturation) *2 > 20% or ferritin > 75 ng/mL at Scr Visit 1*1
  4. Patients being treated with ESAs for as least 4 weeks before Scr Visit 1.
  5. Patients receiving ESAs at protocol specified dose regimen (i.e., frequency and dose)
  6. Patients who have received the same ESA received in most recent week before Scr Visit 1 as during the period between Scr Visit 1 and the day before Week 0 at the same total dose and dosing frequency a week*4.
  7. Patients with pre-dialysis levels measured after the maximum interdialytic interval at Scr Visit 1 and Scr Visit 2 (2 weeks after Scr Visit 1) of ≥ 9.5 g/dL and \< 12.0 g/dL and a difference (in absolute value) between Scr Visit 1 and Scr Visit 2 of ≤1.0 g/dL

Exclusion criteria

Exclusion Criteria:

  1. Patients with poorly controlled hypertension
  2. Patients with severe hepatobiliary disease
  3. Patients with congestive heart failure ( Class III or more) or unstable angina
  4. Patients who have developed myocardial infarction, cerebral infarction (excluding asymptomatic cerebral infarction), or venous thromboembolism (pulmonary embolism or deep vein thrombosis) during the period between 24 weeks before Scr Visit 1 and Week 0.
  5. Patients who will undergo an ophthalmological procedure (photocoagulation therapy or vitreous surgery) for the treatment of diabetic retinopathy, diabetic macular edema, or age- related macular degeneration during the period between Scr Visit 1 and the end of the study
  6. Patients who have undergone erythrocyte transfusion during the period between 12 weeks before Scr Visit 1 and Week 0.
  7. Patients who have received protein anabolic hormones, testosterone enanthate, or mepitiostane during the period between 12 weeks before Scr Visit 1 and Week 0.
  8. Patients with severe hyperparathyroidism
  9. Patients with severe infection, systemic blood disorder (e.g., myelodysplastic syndrome, aplastic anemia, abnormal disease), or hemolytic anemia, or patients with anemia caused by obvious bleeding lesions (e.g., gastrointestinal hemorrhage)
  10. Patients who are suspected to have anemia caused by noninfectious chronic inflammatory disease (e.g., connective tissue disease)
  11. Patients with (including hematological malignancy) or previous history of malignancy during the period between 5 years before Scr Visit 1 and Week 0
  12. Patients with previous history of a serious drug allergy such as anaphylactic shock or a to DA
  13. Patients with current or previous history of drug dependence or alcohol dependence
  14. Patients who have received another product or have received treatment with an investigational device, or have participated in clinical research involving intervention (medical action beyond the scope of ordinary medical practice intended for research purposes) and received treatment within 12 weeks before Scr Visit 1
  15. Patients who have previously participated in a clinical study of JTZ-951 and received the investigational product
  16. Patients who are pregnant, lactating, or may be pregnant (the possibility of pregnancy cannot be ruled out by the PI or the SI based on the results of pregnancy test at Scr Visit 1)
  17. Female patients of who have not agreed to use appropriate methods (medically accepted contraceptive methods: surgical sterilization, intrauterine device, condom, diaphragm, etc.) from the time of signing of to the end of the study, or male patients who have not agreed to use appropriate contraception methods from the start of study treatment to the end of the study.
  18. Other patients who, in the judgment of the PI or the SI, are ineligible for the study
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
172 participants (actual)

Study arms

  • Experimental
    JTZ-951

    Oral doses once daily

    Drug: JTZ-951

  • Active comparator
    Darbepoetin Alfa

    Intravenous doses of Darbepoetin Alfa administered once weekly

    Drug: Darbepoetin Alfa

Interventions

  • Oral tablet * Dose adjustments as maintenance dose is allowed according to the result of Hb level.

    Also known as: enarodustat

  • Intravenous administration * Dose adjustments as maintenance dose is allowed according to the result of Hb level.

    Also known as: Nesp pre-filled syringe

06

What researchers measure

Primary outcomes

  1. Difference in mean Hb level change during the evaluation period from baseline (evaluation period - baseline) between study arm and control arm

    Hb level during the evaluation period is the mean of the Hb levels at Week 20, Week 22 and End of Treatment (Week 24 or at discontinuation).

    Time frame: baseline and Week 20 to 24

  2. Difference in mean Hb level between study arm and control arm during the evaluation period

    Hb level during the evaluation period is the mean of the Hb levels at Week 20, Week 22 and End of Treatment (Week 24 or at discontinuation).

    Time frame: baseline and Week 20 to 24

Secondary outcomes

  1. Proportion of subjects with Hb level within the range of baseline ± 1.0 g/dL at Week 4

    Time frame: Week4

  2. Proportion of subjects with mean Hb level of ≥10.0 g/dL and <12.0 g/dL during the evaluation period

    Time frame: Week 20, 22, 24

  3. Hb level at each Visit

    Time frame: Week 2, 4, 8, 12, 16, 20, 22, 24

  4. Change from baseline in Hb level at each Visit

    Time frame: Week 0, 2, 4, 8, 12, 16, 20, 22, 24

07

Study locations

1 site
  • SMG-SNU Boramae Medical Center
    Seoul, Korea, Republic of
08

References and documents

Publications

  • Natale P, Palmer SC, Jaure A, Hodson EM, Ruospo M, Cooper TE, Hahn D, Saglimbene VM, Craig JC, Strippoli GF. Hypoxia-inducible factor stabilisers for the anaemia of chronic kidney disease. Cochrane Database Syst Rev. 2022 Aug 25;8(8):CD013751. doi: 10.1002/14651858.CD013751.pub2. PubMed 36005278 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2019 to primary completion in Feb 2021, 25 months.

Of 98 industry-sponsored phase 3 interventional studies under Anemia, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 49. This study's 25 months is close to that.

Counting every sponsor, half of 149 studies reached it within 30 months; a quarter within 17 and three quarters within 51.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 10, 2019
First posted
Jul 22, 2019
StartActual
Jan 15, 2019
Primary completionActual
Feb 23, 2021
CompletionActual
Feb 23, 2021
Last update
Mar 22, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 22, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04027517
Lead sponsor
JW Pharmaceutical
Responsible party
Sponsor
First posted
Jul 22, 2019
Start date
Jan 15, 2019
Primary completion
Feb 23, 2021
Completion
Feb 23, 2021
Last update
Mar 22, 2021

Study contacts

Lee
study chair · JW Pharmaceutical

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Enarodustat

Start the discussion